DoMore Diagnostics expands patent coverage for Histotype Px® with grant in South Korea
OSLO – May 15, 2025 – DoMore Diagnostics, a leader in AI and deep-learning precision medicine for cancer, is pleased to announce that Korean patent number 10-2801007 has been granted by the Korean Intellectual Property Office.
This is the first patent granted in Korea and in Asia and extends the global protection of the unique methods underpinning DoMore Diagnostics’ AI-based Histotype Px® digital biomarkers, opening pathways for strategic partnerships and market access across the region. With Asia projected to experience one of the highest increases in cancer incidence globally, the need for reliable and scalable biomarkers has never been more urgent. DoMore Diagnostics’ Histotype Px biomarkers are uniquely positioned to ensure cancer patients get personalized care and at the same time relieve healthcare systems of unnecessary treatment cost and resource use.
“This patent validates and protects the novelty and innovation behind Histotype Px and also signals a growing recognition of AI-driven digital biomarkers in global precision medicine and cancer care,” said Torbjørn Furuseth, CEO and Co-founder of DoMore Diagnostics. “South Korea’s leadership position in medical technology and digital infrastructure combined with recent initiatives to bring novel products faster to patients makes it an ideal entry point into the broader Asian market. This patent is an important step towards increased activity and strategic partnership discussions in the region.”
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Our unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor. DoMore Diagnostics holds a global exclusive license to a portfolio of patents and patent applications owned by Oslo University Hospital, covering the intellectual property underpinning Histotype Px and associated machine learning methods.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefiting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
For more information, please visit:
www.domorediagnostics.com
LinkedIn
The Lancet publication
The Lancet Oncology publication
Contact:
Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com